CAR-T cell therapy targeting B cell maturation antigen (BCMA) relies on the specific recognition of BCMA by a chimeric antigen receptor (CAR) that is introduced into T cells via genetic engineering technology; this therapy makes full use of the immune activity of T cells to accurately attack tumor cells expressing BCMA (2, 3). This evidence concerns the gene TNFRSF17 and neoplasm.